Primary source: Download the Draft Guidance Document
The FDA introduced draft guidance recommending new strategies for potency assessment of active immunotherapy products, which includes specific assay development needs to ensure potency assurance.
This guidance reflects the FDA’s current thinking and may significantly shape how potency is managed and assessed in biologic applications, impacting regulatory compliance and product development strategies.
Stakeholders are advised to submit comments on the draft guidance by 11/18/2026, using docket number FDA-2026-D-8561 to ensure FDA considers their feedback before finalizing the document.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Stakeholders are advised to submit comments on the draft guidance by 11/18/2026, using docket number FDA-2026-D-8561 to ensure FDA considers their feedback before finalizing the document.
The FDA has issued draft guidance titled 'Potency Assessment of Active Immunotherapy Products,' intended for comment, outlining recommendations for developing assays to assess potency in active immunotherapy products (ACTIMPs). While non-binding and not yet for implementation, the document suggests that potency assay requirements may alter current compliance processes in regulatory practices for ACTIMPs.
What changed: The FDA introduced draft guidance recommending new strategies for potency assessment of active immunotherapy products, which includes specific assay development needs to ensure potency assurance.
Why it matters: This guidance reflects the FDA’s current thinking and may significantly shape how potency is managed and assessed in biologic applications, impacting regulatory compliance and product development strategies.
Practical implication: Stakeholders are advised to submit comments on the draft guidance by 11/18/2026, using docket number FDA-2026-D-8561 to ensure FDA considers their feedback before finalizing the document.
Published from the regulator source ingestion pipeline after PV impact triage.
Initiate the update of labeling materials for Rasonque to reflect the new FDA approval and ensure compliance with reporting requirements for newly approved therapies.
Healthcare professionals must include daraxonrasib in adverse event reporting as the new treatment option is now available for eligible patients.
Affected healthcare facilities should remove all Automated Impella Controllers from use and stock, ensure annual preventive maintenance is followed, and report any adverse reactions to Abiomed or MedWatch.
Small business dispensers are encouraged to complete a mandatory assessment survey by September 22, 2026, and do not need to submit information to the FDA while utilizing these exemptions.
